Literature DB >> 8057146

Platelet-derived growth factor expression and stimulation in human meningiomas.

P M Black1, R Carroll, D Glowacka, K Riley, K Dashner.   

Abstract

The platelet-derived growth factor (PDGF) family consists of subunits A and B and receptors alpha and beta. This paper evaluates the potential role of the homodimer PDGF-BB as a growth factor in meningiomas. It analyzes the expression of messenger RNA in members of the PDGF family in these tumors, measures the growth response of meningiomas to exogenous PDGF-BB in culture, and examines the induction of the c-fos proto-oncogene by PDGF-BB. Northern blot analysis was carried out on tissue from 20 meningiomas to measure the expression of PDGF-A, PDGF-B, PDGF-alpha receptor (PDGF-alpha-R) and PDGF-beta receptor (PDGF-beta-R). All tumors expressed PDGF-A and PDGF-B subunits. Nineteen of the 20 tumors expressed PDGF-beta-R and none expressed PDGF-alpha-R as measured by this technique. Because the beta receptor is selectively sensitive to stimulation by the PDGF-B subunit, these data suggest that meningiomas might be susceptible to stimulation by PDGF-BB. To test this hypothesis, the effect of exogenous PDGF-BB on meningioma growth was evaluated by incubating cells from 10 human meningiomas. Tritiated thymidine incorporation was used to evaluate stimulation of growth over a 48-hour period using PDGF-BB concentrations of 1, 3, or 6 ng/ml. Linear regression analysis and multiple-factor analysis of variance were used to measure PDGF-BB effects. Three of the 10 tumor specimens responded significantly to PDGF-BB, with a three- to sixfold increase in thymidine incorporation over 72 hours of exposure, and there was a significant overall growth-stimulating effect of PDGF-BB in the 10 tumor specimens tested. In the last set of experiments, the functionality of the PDGF-beta-R was determined by examining the induction of the proto-oncogene c-fos by PDGF-BB in meningioma cell cultures. A significant increase in c-fos protein was observed 3 hours after PDGF-BB addition. These findings demonstrate that PDGF-A, PDGF-B, and PDGF-beta-R are expressed in meningiomas and suggest that the beta receptor is functional: when it is activated, c-fos levels are increased, and an increase in meningioma cell division is observed after the addition of PDGF-BB. These studies support the hypothesis that PDGF acts as a growth factor in meningiomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057146     DOI: 10.3171/jns.1994.81.3.0388

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  20 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Authors:  David A Reardon; Andrew D Norden; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; John H Sampson; Sridharan Gururangan; Katherine B Peters; Roger E McLendon; Julie A Norfleet; Eric S Lipp; Jan Drappatz; Patrick Y Wen; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

3.  Two distinct primary brain tumors, in same region of the same patient: a case report.

Authors:  Bekir Tugcu; Umit Kepoglu; Murat Gunal; Omur Gunaldi; Bluent Karakaya; Bluent T Demirgil
Journal:  J Neurooncol       Date:  2006-03-24       Impact factor: 4.130

Review 4.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

5.  Expression of TGFalpha in meningiomas.

Authors:  J Halper; C Jung; A Perry; H Suliman; M P Hill; B Scheithauer
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  A novel class of interstitial cells in the mouse and monkey female reproductive tracts.

Authors:  Lauren E Peri; Byoung H Koh; Grace K Ward; Yulia Bayguinov; Sung Jin Hwang; Thomas W Gould; Catrina J Mullan; Kenton M Sanders; Sean M Ward
Journal:  Biol Reprod       Date:  2015-03-18       Impact factor: 4.285

Review 7.  Pathogenesis of peri-tumoral edema in intracranial meningiomas.

Authors:  Moncef Berhouma; Timothee Jacquesson; Emmanuel Jouanneau; François Cotton
Journal:  Neurosurg Rev       Date:  2017-08-24       Impact factor: 3.042

8.  Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.

Authors:  Peter Horak; Adelheid Wöhrer; Marco Hassler; Johannes Hainfellner; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

9.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 10.  The biology of meningiomas.

Authors:  I E McCutcheon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.